10-Q: Progyny Reports Q2 2026 Growth Amidst Increased Operating Costs

Progyny, Inc. announced its Q2 2026 results, showcasing a 5% increase in revenue driven by its fertility and pharmacy benefits solutions, alongside a notable improvement in gross margin.

Summary

• Progyny reported a 5% increase in revenue for the three months ended June 30, 2026, reaching $350.5 million, compared to $332.9 million in the prior year period.
• For the six months ended June 30, 2026, revenue grew 3% to $679.0 million from $656.9 million in the same period last year.
• Gross profit increased by 13% to $89.3 million for the quarter and by 11% to $172.4 million for the six-month period.
• Gross margin improved to 25.5% for the quarter and 25.4% for the six-month period, up from 23.7% and 23.6% respectively.
• Net income for the quarter was $28.1 million, a decrease from $17.1 million in the prior year, while diluted EPS was $0.34 compared to $0.19.
• For the six-month period, net income was $52.3 million, up from $32.2 million in the prior year, with diluted EPS of $0.63 compared to $0.36.
• Operating expenses increased due to higher personnel costs and investments in growth initiatives.
• The company ended the period with $152.6 million in cash and cash equivalents and $84.3 million in marketable securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting continued revenue growth and improved gross margins, though tempered by increased operating expenses and a slight decrease in net income compared to the prior year's comparable period.

Positives

• Revenue increased by 5% to $350.5 million for the three months ended June 30, 2026, and by 3% to $679.0 million for the six months ended June 30, 2026.
• Gross profit saw a significant increase of 13% to $89.3 million for the quarter and 11% to $172.4 million for the six-month period.
• Gross margin improved by 180 basis points to 25.5% for the quarter and 25.4% for the six-month period, indicating improved operational efficiencies.
• The company ended the period with a strong liquidity position, holding $152.6 million in cash and cash equivalents and $84.3 million in marketable securities.
• Client base grew to 604 clients from 555 clients, representing 7.2 million covered lives.
• Assisted Reproductive Treatment (ART) cycles remained stable year-over-year, with a slight increase in utilization rates.
• The company continues to expand its offerings beyond fertility, including pregnancy and postpartum, menopause and midlife, and other women's health solutions.

Negatives

• Net income for the three months ended June 30, 2026, decreased to $28.1 million from $17.1 million in the prior year period, impacted by higher operating expenses.
• Diluted earnings per share for the three months ended June 30, 2026, decreased to $0.34 from $0.19 in the prior year period.
• Total operating expenses increased by 14% for the quarter and 11% for the six-month period, primarily driven by increased personnel-related costs and investments in growth.
• Stock-based compensation expense decreased significantly, but overall personnel costs increased due to incremental headcount.
• Interest and other income, net, decreased by 58% for the quarter and 48% for the six-month period, primarily due to lower interest income.

Risks

• Failure to meet publicly announced guidance or other expectations could cause the stock price to decline.
• Intense competition in the market could harm the company's business, financial condition, and results of operations.
• Unfavorable global economic conditions or industry downturns could limit growth and negatively affect results.
• Dependence on retaining existing clients and increasing adoption of services within the client base is critical.
• Loss of significant clients, particularly in the technology sector, or changes in pricing terms could negatively impact the business.
• Inability to attract new clients could adversely affect financial performance.
• Changes in the utilization rate or mix of solutions could have an adverse effect on financial results.
• Operating in a highly regulated industry requires compliance with evolving legal and regulatory requirements.

Future Outlook

The company believes its existing cash, cash equivalents, marketable securities, and operating cash flow, along with its revolving credit facility, will be sufficient to support working capital and capital expenditure requirements for at least the next 12 months. Future capital requirements will depend on sales, client renewals, client payment timing, investments in benefits offerings and growth strategy, sales and marketing expansion, and market adoption. The company may seek additional equity or debt financing if needed.

Management Comments

• The company has grown its client base to more than 600 employers, covering approximately 7.2 million employees and dependents.
• Progyny's platform consistently delivers superior clinical outcomes in a cost-efficient manner, driving exceptional client and member satisfaction.
• The company has retained substantially all of its clients since launching its fertility benefits solution.
• Net Promoter Scores (NPS) remain industry-leading at +81 for fertility benefits and +79 for Progyny Rx as of December 31, 2025.
• The company continues to expand its women's health and family building solutions beyond fertility.

Industry Context

StockSavvy.ai notes that Progyny operates in the growing health benefits management sector, focusing on fertility and women's health. The company's performance reflects broader trends of employers seeking specialized benefits to attract and retain talent, particularly in competitive industries like technology. The increasing focus on comprehensive family-building and women's health solutions aligns with evolving employee expectations and healthcare industry shifts.

Comparison to Industry Standards

• Progyny's in-network provider clinic averages show a live birth rate per attempted retrieval of 46.7%, significantly higher than the national average of 34.9% (SART 2021 data).
• The single embryo transfer rate for Progyny members is 96.6%, substantially exceeding the national average of 78.9%.
• The miscarriage rate for Progyny members is 14.4%, lower than the national average of 18.2%.
• The IVF multiples rate for Progyny members is 2.1%, considerably lower than the national average of 5.8%.
• Net Promoter Scores (NPS) of +81 for fertility benefits and +79 for Progyny Rx are cited as industry-leading, indicating high member satisfaction compared to typical industry benchmarks.

Legal Proceedings

• The company is not aware of any legal proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its financial position or results of operations.

Stakeholder Impact

• Shareholders: Continued revenue growth and improved gross margins are positive, but increased operating expenses and a slight decrease in quarterly net income may temper short-term investor sentiment. Share repurchase programs may provide some support.
• Employees: Stock-based compensation expense has decreased, but overall personnel costs have increased due to headcount growth, indicating continued investment in human capital.
• Clients: Continued growth in client base and member lives, along with industry-leading NPS scores, suggest strong client satisfaction and retention.
• Providers/Pharmacies: The company relies on its network of fertility specialists and specialty pharmacies; maintaining these relationships and managing costs within these networks is crucial for service delivery and profitability.

Next Steps

• Continue to invest in sales and marketing to drive new client acquisition.
• Expand offerings in pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions.
• Continue to invest in technology infrastructure, including systems architecture, scalability, availability, performance, and security.
• Monitor and adapt to evolving legal and regulatory requirements in the healthcare industry.
• Manage and maintain relationships with the Center of Excellence network of fertility specialists and other healthcare providers.
• Maintain an efficient pharmacy distribution network and monitor specialty pharmacy partners.

Key Dates

Recommendation

Progyny demonstrates consistent revenue growth and improving gross margins, driven by strong client retention and expansion in its core fertility and pharmacy benefits solutions. However, the increase in operating expenses, particularly personnel costs, and a slight year-over-year decrease in quarterly net income, alongside the inherent risks in the highly regulated healthcare industry and competitive landscape, suggest a 'hold' rating. While the company's market position and clinical outcomes are strong, the current growth trajectory and cost pressures warrant a cautious approach until sustained profitability improvements are evident.

Keywords

fertility benefits, family building, women's health, pharmacy benefits, PBM, employer benefits, healthcare solutions, Smart Cycles